OncLive TV

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.

Antonio González-Martín, MD, discusses the design of the PRIMA trial in ovarian cancer.

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses the impact of the VELIA trial on ovarian cancer practice.

Benjamin Leon Musher, MD, discusses the current treatment options for patients with hepatocellular carcinoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses investigational targeted therapies in metastatic colorectal cancer (mCRC).